| 28.2 -0.04 (-0.14%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 35.02 |
1-year : | 37.21 |
| Resists | First : | 29.98 |
Second : | 31.86 |
| Pivot price | 28.39 |
|||
| Supports | First : | 26.95 | Second : | 22.43 |
| MAs | MA(5) : | 28.97 |
MA(20) : | 28.79 |
| MA(100) : | 36.92 |
MA(250) : | 39.48 |
|
| MACD | MACD : | -1.1 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 50.9 |
D(3) : | 57 |
| RSI | RSI(14): 38.3 |
|||
| 52-week | High : | 54.84 | Low : | 26.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HROW ] has closed above bottom band by 43.2%. Bollinger Bands are 57.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 30.07 - 30.23 | 30.23 - 30.32 |
| Low: | 27.74 - 27.93 | 27.93 - 28.05 |
| Close: | 27.96 - 28.25 | 28.25 - 28.44 |
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Tue, 13 Oct 2026
Harrow (NasdaqGM:HROW) Stock Forecast & Analyst Predictions - Simply Wall St
Tue, 12 May 2026
Harrow Inc (HROW) Q1 2026 Earnings Call Highlights: Strong Product Demand Amid Revenue Challenges - Yahoo Finance
Mon, 11 May 2026
Harrow Announces First Quarter 2026 Financial Results - Yahoo Finance
Mon, 09 Mar 2026
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions - Yahoo Finance
Mon, 02 Oct 2023
Harrow, Inc. Stock (HROW) - Quote Nasdaq - marketscreener.com
Mon, 02 Oct 2023
Harrow, Inc.: Target Price Consensus and Analysts Recommendations | HROW | US4158581094 - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 37 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 58.5 (%) |
| Shares Short | 7,760 (K) |
| Shares Short P.Month | 6,780 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | -13.6 % |
| Operating Margin | -15.6 % |
| Return on Assets (ttm) | -0.5 % |
| Return on Equity (ttm) | -116.1 % |
| Qtrly Rev. Growth | 10.8 % |
| Gross Profit (p.s.) | 5.38 |
| Sales Per Share | 7.35 |
| EBITDA (p.s.) | 0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -28.49 |
| PEG Ratio | 0 |
| Price to Book value | 68.78 |
| Price to Sales | 3.83 |
| Price to Cash Flow | 169.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|